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The tumor necrosis factor receptor superfamily (TNFRSF), which includes CD40, LIGHT, and OX40, plays important roles in the initiation
and progression of cardiovascular diseases, involving atherosclerosis. CD137, a member of TNFRSF, is a well-known activation-induced T
cell co-stimulatory molecule and has been reported to be expressed in human atherosclerotic plaque lesions, and plays pivotal roles in
mediating disease processes. In this review, we focus on and summarize recent advances in mouse studies on the involvement of CD137
signaling in the pathogenesis and plaque stability of atherosclerosis, thereby highlighting a valuable therapeutic target in atherosclerosis.
(Korean Circ J 2016;46(6):753-761)
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Introduction
Atherosclerosis, a disease of blood vessel walls characterized
by thickening of the artery walls,1)2) is a chronic inflammatory
disease in which immunological pathways play essential roles.3)4)
Atherosclerotic plaques contain immune cells, vascular cells (i.e.
endothelial cells and vascular smooth muscle cells), extracellular
matrix, cellular debris, and lipids. During the initial stage of plaque
formation, lipids accumulate in the intima, where these lipids,
such as low-density lipoprotein (LDL), are modified by oxidation
or by enzymes to form oxidized LDL (oxLDL), and a chronic
inflammatory response develops to these modified lipids. Lipidladen macrophages known as foam cells are the most prevalent
cells in early atherosclerotic plaque lesions (fatty streaks), although
these plaques also contain T cells. Inflammatory cytokines
produced by the accumulated immune cells, which include T
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cells and antigen presenting cells (APCs), such as macrophages
and dendritic cells (DC) that present antigenic peptides including
oxLDL, affect the development of atherosclerosis.5-7) Over time,
fatty streaks can progress into mature, advanced atherosclerotic
plaques. Mature plaques generally have abundant accumulation
of macrophages and T cells. These immune cells are activated
and produce high levels of inflammatory cytokines such as INF-γ
and tumor necrosis factor (TNF). When these plaques progress
into more complex lesions, the lipid core region becomes a large
necrotic core attributing to the death of macrophages and vascular
smooth muscle cells (VSMCs)8)9) and elevated levels of matrix
metalloproteinases (MMPs), which degrade the extracellular matrix,
leading to weakened fibrous caps.10)11) Moreover, mature plaques
are more prone to rupture, causing atherothrombotic vascular
conditions such as a myocardial infarction. However, there are
presently no established atherosclerotic plaque rupture murine
models.
CD137 is a member of tumor necrosis factor receptor
superfamily (TNFRSF), and its alternative names are TNFRSF9,
4-1BB, and induced by lymphocyte activation (ILA). CD137 was
originally discovered on activated T cells, so the best characterized
function of CD137 is its co-stimulatory activity for activated T
cells. Interaction of CD137 and its ligand CD137L enhances T cell
proliferation, effector function, and survival. Among the various
animal disease models, CD137 was the most investigated target
molecule in tumor models.12) It has been reported that CD137 is
expressed on a wide range of tumor cells,13) and both in tumor
vessel walls and tumor-liver tissue in patients with cancer.14)15)
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Therefore, many investigators have studied the anti-tumor effects
of CD137 as a therapeutic agent.
Accordingly, recent studies referred to CD137 and its ligand
CD137L signaling as a potential biomarker between the immune
system and cardiovascular disease including atherosclerosis. This
signaling could be an important therapeutic target for development
and plaque stability of atherosclerosis. Here, we discuss the
characteristics of CD137 in immune and vascular cells, and its role
as the diagnosis biomarker for the development of atherosclerosis.

T cells in atherosclerosis
T helper (Th) cells
T cells are present at all developmental stages of atherosclerotic
plaques (~10% of plaques); they and their cytokines play
important roles in disease processes.16)17) The majority of T cells
in mouse and human atherosclerotic plaque are CD4+ T cells that
express the αβ T cell receptor (TCR) and have an effector T cell
phenotype. With respect to cytokine profiles, effector T cells are
functionally classified as T helper cell type 1 (Th1), Th2, or Th17. It
has been demonstrated that the Th1 response in atherosclerosis
shows predominantly pro-atherogenic potential. Th1 cells are
characterized by their prominent production of pro-inflammatory
cytokines, including interferon (IFN)-γ, tumor necrosis factor
(TNF)-α, interleukin-2 (IL-2), and IL-7, which activate macrophages
as well as other immune cells. The interaction of the T cell receptor
(TCR) on activated Th1 cells with major histocompatibility complex II
(MHC II)-binding antigen peptides delivered by APCs synergistically
induces the bidirectional activation of both cell types.18-20) T cell
activation is further enhanced by ligand binding to co-stimulatory
receptors including CD40, CD137, and OX40, which are expressed
on the cell surface. Enhanced T cell activation by ligand binding to
co-stimulatory receptors significantly augments cytokine release
by monocytes/macrophages, further exacerbating inflammation
and promoting atherosclerosis.21)22) Th2 cells produce Th2-related
cytokines, including IL-4, IL-5, and IL-13, which are known to
antagonize Th1 effects and thereby produce atheroprotective
effects.23)24) However, the role of the Th2 response during the
development of atherosclerosis remains uncertain, seemingly
depending on the stage of the atherosclerotic lesion formation
or the experimental mice model employed. Recently, there has
been research focused on IL-17-producing Th17 cells, which play
important roles in the pathogenesis of atherosclerosis. Studies on
atherosclerosis have led to conflicting results regarding the role of
Th17 cells in disease development. IL17-A and IL-17A expressing T
cells (Th17) were significantly increased in ApoE-/- mice compared
http://dx.doi.org/10.4070/kcj.2016.46.6.753

with age-matched C57BL/6 mice. When feeding them a high fat
diet, Th17 cells were elevated in the aorta. Blockade of IL-17A in
ApoE-/- mice by use of adenovirus-produced IL-17 receptor A (IL17RA) reduced the formation of atherosclerotic plaque. In the
study using genetically deficient IL-17A and IL-17 RA in ApoE-/- mice,
IL-17A/IL-17RA axis increase aortic arch inflammation through the
induction of aortic chemokines and leukocytes recruitment during
atherogenesis.25)26) In contrast, several studies suggested that IL17 production protects against vascular inflammation and plaque
formation in Ldlr-/- mice, and supplementation with IL-17 reduces
vascular inflammation and limits development of atherosclerotic
plaque. And IL-17A mainly produced by Th17 cells plays a antiatherogenic role in a myocardial injury.27)28)
Regulatory T (Treg) cells
As atherosclerosis is a chronic inflammatory disease, and Th1type cytokines dominate in mouse and human atherosclerotic
plaques, immune homeostasis is crucial for protection and
stabilization of atherosclerotic plaques. Two anti-inflammatory
cytokines, interleukin-10 (IL-10) and transforming growth
factor-β (TGF-β), are counterbalancing cytokines that dampen
disease activity. Several cell types can produce IL-10 and TGF-β,
including platelets, M2 macrophages, endothelial cells, vascular
smooth muscle cells, and regulatory T (Treg) cells. CD4+CD25+ Treg
cells constitute 5-10% of peripheral CD4+ T cells, which actively
maintain an immunological tolerance to self-antigens, and control
the development and progression of atherosclerosis.29-31) Treg cells
actively suppress activation or effector functions of Teff cells,
either directly or through effects on APCs. Foxp3, an X-linked
transcription factor that is highly and specifically expressed in Treg
cells, is a lineage specification factor and has a critical role in Treg
suppressive function.32)33) CD4+CD25+ Treg cells are produced in the
thymus as a functionally mature subpopulation of T cells (natural
Treg, nTreg) and can also be induced from naïve T cells in the periphery
(adaptive Treg). Deficiencies in the development or function of
these cells are associated with severe autoimmune inflammatory
diseases. Many studies have suggested that Treg cells are important
regulators in the development of atherosclerosis.34) Many studies
have suggested that Treg cells were found in both mouse and
human atherosclerotic plaques and showed that Treg numbers are
reduced during atherosclerosis. In a mouse study, ApoE-/- mice
have reduced numbers of Treg cells compared with C57BL/6 mice,35)
and feeding with a high fat diet also induced a reduction in Treg
cells compared with mice fed a regular normal chow diet.36) Also,
deficiency of Treg cells has been reported to increase atherosclerosis
and plaque inflammation,37)38) and the anti-inflammatory cytokines
produced from Treg cells, IL-10 and TGF-β, have been shown to
www.e-kcj.org
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attenuate the development of atherosclerosis.39) In many studies
of Treg cells functioning during this disease, Treg cells showed the
ability to inhibit both IFN-γ producing Th1 and IL-17 producing Th17
subsests of Teff cells.40) Treg cells can also inhibit pro-atherogenic
macrophage inflammation by promoting the differentiation of
M1 macrophages towards anti-inflammatory M2 macrophages.
Therefore, expansion of Treg cells enhanced atherosclerotic plaque
stability by inducing collagen producing M2 macrophages. Treg cells
reduces the transition of macrophages into foam cells by inhibiting
lipid accumulation via down-regulation of scavenger receptor
class A (SR-A), and CD36.41) In addition, overexpression of IL-10
reduces VLDL, LDL levels in Ldlr-/- mice,34) and adaptive transfer of
Treg cells also inhibit endothelial activation, leading to reduction of
leukocytes attachment.42)

Co-stimulatory molecules and receptors
As stated above, T cells are initially activated by the interaction
of TCR and MHC-binding antigen peptides delivered by APCs to
proliferate and differentiate into Teff cells. In contrast to this
antigen-specific first signal, the second signal for T cell activation is
antigen-non specific and generated by co-stimulatory molecules.
At each stage, T cells are activated by the combination of these
two signals, both delivered by APCs. Dendritic cells (DCs), major
member of the APCs, can initiate activation of T cells by presenting
antigens into MHC-binding peptides.43)44) Co-stimulatory pathways
are necessary for T cell activation; many studies have suggested
that their absence can lead to functional inactivation of T cells, and
cause T cell death by apoptosis. Therefore, these co-stimulatory
signals play a critical role in the induction of an adaptive response,
and provides a mechanism to communicate immunological danger
to the adaptive immune system.45)46) Both APCs and adaptive
immune cells (T and B cells) respond to receptor signaling generated
by co-stimulatory ligands. B cells also require two types of signals
to become activated and produce antibodies. B cell binds antigens
with its BCR (B cell receptor, a membrane-bound antibody) as a first
signal. And activated T cells generally provide the second signal for
B cell activation through co-stimulatory secondary signals, leading
to mount a humoral response.47) The interaction between T cells
and B cells mediated by this signaling pathway is responsible for
B cell proliferation and differentiation, immunoglobulin isotype
switching, and antibody secretion. There are two families of costimulatory molecules, namely the B7 family and the tumor
necrosis factor superfamily (TNFSF). Several members of the
TNFRSF, including CD40, LIGHT, CD134 (OX40), and CD137, have
been shown to carry out important immune modulatory functions
www.e-kcj.org

in atherosclerosis.48-51)
CD137 and CD137L
CD137 is a 30 kDa type I transmembrane glycoprotein, and is a
well-known T cell co-stimulatory molecule. Expression of CD137
is activation dependent. CD137 is not detected (<3%) on resting T
cells or naïve T cells. However, CD137 is upregulated when T cells
are activated upon stimulation. CD137 has been reported to be
expressed on most immune cells, including activated CD4+ and
CD8+ T cells, natural killer (NK) cells, NKT cells, and CD4+CD25+ Treg
cells. CD137 is also expressed on myeloid cells, such as monocytes,
neutrophils, mast cells, eosinophils, and dendritic cells.52-54) In
vascular cells such as endothelial cells and vascular smooth muscle
cells, CD137 is expressed in an activation-dependent manner.
CD137L, a ligand for CD137, is a type II membrane glycoprotein of
the TNF superfamily that is expressed on APCs such as monocytes,
macrophages, dendritic cells, and activated B cells. In general,
TNFRSF members are initiators of inflammatory diseases. CD137deficient mice have been used in an attempt to define the role of
CD137 in the immune system and in immune-related diseases.
CD137-deficient mice have been shown to exhibit an enhanced T
cell response, but have normal T cell development.55)56) Vinay and
colleagues also showed that CD137-deficient mice have a reduced
number of natural killer cells and natural killer T cells, which leads
to a resistance to lipopolysaccharide-induced shock syndrome.57)
In a dendritic cell study, CD137 was found to be a crucial survival
factor58) and to control certain regulatory activities by promoting
production of retinal dehydrogenase.59) Therefore, CD137 appears
to play a variety of roles in the immune system.
CD137 and CD137L in atherosclerosis
With regard to the formation of atherosclerotic plaque lesions, a
few studies have reported that CD137 and CD137L play critical roles
in this process. For example, Olofsson and colleagues observed
clear CD137 expression in human atherosclerotic plaques.50) They
also showed that CD137 was expressed on T cells and endothelial
cells in human atherosclerotic plaque lesions. CD137 is inducible
in vascular cells, including endothelial cells and vascular smooth
muscle cells, in vitro. In clinical studies, CD137 expression is
known to be involved in the stability of coronary atherosclerotic
plaques.60)61) Patients with ACS (acute coronary syndromes)
showed both increased levels of CD137 expression in monocytes
and soluble CD137 in serum compared with control and SA (stable
angina) group, deriving a conclusion of positive relationship
between CD137 expression and increase in serum MMP-3, and
MMP-9 in patients with ACS. In addition, Patients with ACS
showed an increase in both soluble and membrane-bound CD137
http://dx.doi.org/10.4070/kcj.2016.46.6.753
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Fig. 1. Proposed model for CD137 signaling in the development of mouse atherosclerosis and maintenance of plaque stability therein. Teff: effector T, EC:
endothelial cell, VSMC: vascular smooth muscle cell, TCR: T cell receptor, MHCII: major histocompatibility complex II, VCAM-1: vascular cell adhesion
molecule-1, ICAM-1: intercellular adhesion molecule-1, TNF-α: tumor necrosis factor alpha, MCP-1: monocyte chemo-attractant protein-1, IL: interleukin,
IFN-γ: interferon gamma, MMP: matrix metalloproteinase protein.

expression, leading to a positive correlation with the CRP level in
patients with ACS. Therefore, we speculate that CD137 could be a
typical marker for instability of atherosclerotic plaques in patients
with ACS. CD137-CD137L interaction induces activation of the
phospholipase C (PLC) signaling a pathway in human umbilical
vein endothelial cells (HUVECs).62) Both plasma-soluble CD137L and
CD137L expression on monocytes were upregulated in patients
with atherothrombotic stroke63) and acute coronary syndrome.64)
Based on results of a study using an atherosclerotic mouse model,
it has been suggested that CD137-CD137L interaction regulates
atherosclerosis via cyclophilin A.65) Our group previously showed
that CD137 deficiency reduced the formation of atherosclerotic
plaque lesions in a mouse atherosclerosis model.51) Briefly, we
found the molecular mechanisms whereby CD137-CD137L
interaction induces activation of macrophages and Teff cells
through bidirectional signaling. Activated Teff cells produce more
IFN-γ, which leads to recruitment and activation of macrophages.
The activated macrophages produce more TNF-α and MCP-1,
which cause endothelial CD137 expression. This endothelial CD137
signaling induces the production of MCP-1 and cell adhesion
molecules, probably leading to enhancement of leukocyte
recruitment to the lesion (Fig. 1).

http://dx.doi.org/10.4070/kcj.2016.46.6.753

Advanced, vulnerable plaque
During the progression of atherosclerosis, lipids and leukocytes
accumulate in the intima, causing activation of the immune
system. Inflammatory cytokines produced by the accumulated
immune cells, including T cells and APCs, affect the development of
atherosclerosis. Over time, mature plaques develop into vulnerable
plaques, which are more prone to rupture, causing subsequent
atherothrombotic vascular conditions such as myocardial infarction.
Therefore, lesion growth in advanced plaques differs significantly
from early lesions.
Pathological features of vulnerable plaques
Vulnerable plaques generally have a large necrotic core, which is
attributed to the death of macrophages and vascular smooth muscle
cells (VSMCs). Ruptured plaques are characterized by a necrotic
core with an overlying thin fibrous cap infiltrated by macrophages
and lymphocytes. The extracellular matrix, which includes collagen
fibers, normally confers biochemical stability to the fibrous cap
of the atherosclerotic plaque. Vulnerable plaques have elevated
levels of matrix metalloproteinases (MMPs), which may degrade
the extracellular matrix, leading to weakened fibrous caps. These
proteolytic enzymes released from macrophages in atherosclerotic
www.e-kcj.org
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causes overproduction of matrix-degrading proteases, including
MMP-1, 8, and 13, that induce collagen breakdown.82) A recent
mouse study found that CD40 is involved in atherosclerotic plaque
stability.48) Deficiency of CD40 reduced atherosclerosis and led
to a stable atherosclerotic plaque phenotype by inducing plaque
fibrosis and the M2 macrophage phenotype. However, deficiency
of CD40 did not affect apoptosis of cells in atherosclerotic plaque
lesions. In addition, OX40 (TNFRSF4) and its ligand OX40L (TNFSF4)
in CD4 T+ lymphocytes were highly upregulated,83) and both OX40L
on platelets and soluble OX40L in serum were increased in patients
with acute coronary syndrome.84) It has been suggested that LIGHT
(TNFSF14) and LIGHTR (LIGHT receptor, TNFRSF14) are expressed in
atherosclerotic plaques, and decrease plaque stability by inducing
the expression of TNF-α, IL-8, and MMPs.85) Furthermore, activation
of TNFRSF12 induces MMP expression, leading to destabilization of
atherosclerotic plaques.86)

plaques exacerbate matrix degradation, leading to lesion
instability.66) Previous studies in a mouse model of atherosclerosis
suggested that levels of MMP-2 and MMP-9 increase during
atherosclerosis, and that MMP-2 and MMP-9 expression largely
depends on bone marrow-derived macrophages.67-69) Furthermore,
it has been suggested that over expression of MMP-2 and MMP9 in macrophages induces vulnerable features of plaques.70)71)
Cathepsins, a subset of cysteine proteinases, have pivotal roles
during atherosclerosis. Previous mouse studies have suggested
that cathepsin L stimulates autophagy and inhibits endothelial cell
apoptosis.72) Deficiency in either cathepsin L or cathepsin S reduces
the development of atherosclerosis.73)74) Leukocyte cathepsin K is an
important factor in atherosclerotic plaque vulnerability and vascular
remodeling.75-77) It has been suggested that the pro-inflammatory
cytokine IFN-γ secreted from activated T cells (Th1) inhibits the
synthesis of new collagens by VSMCs in advanced vulnerable
plaques, and also inhibit the proliferation and expression of
smooth muscle alpha actin of VSMCs.78)79) In this pro-inflammatory
condition, VSMCs could be main targets for pro-inflammatory
mediators, and growth factors like platelet-derived growth factor
(PDGF) as well as injured vascular endothelial cells (ECs) and VSMCs
themselves, leading to quiescent healthy VSMCs into a proliferative
synthetic form, a so called “phenotype change”.80)81)

CD137 and vulnerable plaques
Olofsson and colleagues50) suggested that CD137 was induced in
VSMCs by proinflammatory cytokines in atherosclerotic plaques, and
that stimulation of these VSMCs with CD137L reduced proliferation.
These results indicated that CD137 signaling may contribute to
the destabilization of atherosclerotic plaques. Recently, our group
determined the CD137-mediated molecular mechanisms whereby
activation of CD137 signaling decreases the stability of advanced
atherosclerotic plaques via its combined effects on Teff cells, VSMCs,
and macrophages.87) Briefly, CD137 increases the infiltration

TNFSF/TNFRSF and vulnerable plaques
A recent study suggested that ligation of CD40 (TNFRSF5)
expressed on macrophages to CD40L (TNFSF5) expressed on T cells

Immune cells
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Fig. 2. Functional effects of CD137 signaling in immune cells and vascular cells involved in atherosclerotic plaques. Teff: effector T, Treg: regulatory T, EC:
endothelial cell, VSMC: vascular smooth muscle cell, DC: dentritic cell, VCAM-1: vascular cell adhesion molecule-1, ICAM-1: intercellular adhesion
molecule-1, TNF-α: tumor necrosis factor alpha, MCP-1: monocyte chemo-attractant protein-1, IL: interleukin, IFN-γ: interferon gamma, MMP: matrix
metalloproteinase protein.
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of Teff cells into plaque lesion sites, resulting in increased IFN-γ
expression. Teff cell-derived IFN-γ then inhibits collagen synthesis
in atherosclerotic plaques. Furthermore, CD137 activation leads
to increased apoptosis of VSMCs, possibly by decreasing the antiapoptotic regulator, Bcl-2, and subsequently upregulating a cleaved
caspase-3. In macrophages, activation of CD137 signaling boosts
the oxidized low-density lipoprotein-induced expression of MMP9 via the p38 mitogen-activated protein kinase and extracellular
signal-regulated kinase 1/2 signaling pathways (Fig. 1).
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